This company is no longer active
The company may no longer be operating, as it may be out of business. Find out why through their latest events.
Ekso Bionics Holdings Zukünftiges Wachstum
Future Kriterienprüfungen 5/6
Für Ekso Bionics Holdings wird ein Gewinn- und Umsatzwachstum von 74.9% bzw. 23.2% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 92.5% pro Jahr steigen soll.
Wichtige Informationen
74.9%
Wachstumsrate der Gewinne
92.48%
EPS-Wachstumsrate
| Medical Equipment Gewinnwachstum | 17.1% |
| Wachstumsrate der Einnahmen | 23.2% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 31 Dec 2025 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrative-Update • Apr 23
EKSO: Going Concern Warning Will Drive Bearish Outlook On Shares
Analysts have maintained their $9.50 price target for Ekso Bionics Holdings, noting that only modest adjustments were made to inputs such as the discount rate, revenue growth, profit margin and future P/E assumptions, rather than any major change to the overall investment case. What's in the News Auditor WithumSmith+Brown, PC issued an unqualified opinion in the 10-K filed on February 23, 2026, while also expressing doubt about Ekso Bionics Holdings' ability to continue as a going concern, highlighting liquidity and sustainability questions for shareholders (Key Developments).Narrative-Update • Apr 09
EKSO: Going Concern Risk And Capital Raises Will Shape Balanced Outlook
Analysts have kept their $9.50 price target for Ekso Bionics Holdings unchanged, pointing to only minor tweaks to inputs such as discount rate, revenue growth, profit margin, and future P/E assumptions as the reason for holding steady. What's in the News Filed Form 10-K for the year ended December 31, 2025, with auditor WithumSmith+Brown, PC issuing an unqualified opinion that includes doubt about Ekso Bionics Holdings continuing as a going concern (10-K filing).Narrative-Update • Mar 25
EKSO: Reverse Merger And Going Concern Risk Will Drive Bearish Outlook
Analysts have modestly adjusted their price target for Ekso Bionics Holdings, citing small updates to inputs such as the discount rate, an assumed long term revenue growth rate of about 33.71%, and a future P/E assumption of about 43.20x. Taken together, these inputs leave their view of fair value steady at $9.50 per share.Narrative-Update • Mar 11
EKSO: Reverse Merger Uncertainty Will Drive Bearish Long Term Outlook
Analysts have nudged their price target on Ekso Bionics Holdings higher to $9.50 per share, reflecting updated assumptions around revenue growth, profit margin and a lower forward P/E. Together, these factors support a stronger long term valuation case at the same fair value estimate of $9.50.Narrative-Update • Feb 24
EKSO: Reverse Merger And Revenue Slowdown Will Shape Cautious Outlook
Analysts have maintained their $9.50 price target on Ekso Bionics Holdings, citing only minor adjustments to inputs such as the discount rate, long term revenue growth assumptions, profit margin and future P/E that do not materially alter their valuation view. What’s in the News Applied Digital Cloud Corporation signed a letter of intent to acquire Ekso Bionics Holdings in a reverse merger, with Applied Digital expected to own about 97% of the combined company.Narrative-Update • Feb 10
EKSO: Q3 Sales Recovery And Business Review Will Shape Balanced Outlook
Analysts have lifted their price target on Ekso Bionics Holdings to US$6 from US$4, citing a solid Q3 update and a company-led review of its current business as key supports for the revised valuation outlook. Analyst Commentary Bullish Takeaways Bullish analysts point to the higher US$6 price target as a reflection of increased confidence in the company’s ability to execute on its current business plan following the Q3 update.Narrative-Update • Jan 27
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Narrative Update Analysts have lifted their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 report, a newly announced review of the current business, and signs that earlier order delays may have been specific to prior periods rather than ongoing. Analyst Commentary Analysts raising their price target to $6 from $4 are reacting to the recent Q3 report and the announced review of the current business, while still flagging a few key execution risks that could affect how the story plays out from here.Narrative-Update • Jan 12
EKSO: Q3 Sales Recovery And Business Review Will Support Future Upside
Analysts have lifted their fair value estimate for Ekso Bionics Holdings from $7.75 to $9.50, citing a higher Street price target of $6.00, a solid Q3 report, and the ongoing review of the current business as key reasons for the reassessment. Analyst Commentary Recent Street research reflects a mix of optimism and caution around Ekso Bionics Holdings, with the latest price target move to US$6 framed around the recent Q3 report and the ongoing review of the current business.Narrative-Update • Dec 26
EKSO: Q3 Sales Recovery And Business Review Will Drive Future Upside
Analysts have modestly raised their price target on Ekso Bionics Holdings to $6 from $4, citing a solid Q3 performance and signs that earlier order delays were idiosyncratic, even as they await further confirmation that the recent sales recovery is sustainable. Analyst Commentary Bullish analysts view the higher price target as a reflection of improving execution and a clearer path to value creation following the strong Q3 report and strategic review announcement.Analyseartikel • Dec 23
Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Shares Bounce 29% But Its Business Still Trails The Industry
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a really impressive month, gaining 29% after a shaky period...
Narrative-Update • Dec 12
EKSO: Q3 Sales Momentum Is Expected To Drive Shares Higher
Analysts have raised their price target on Ekso Bionics Holdings to $6.00 from $4.00, citing stronger than expected Q3 sales momentum, a modestly lower perceived risk profile, and improved long term growth and profitability assumptions. Analyst Commentary Bearish analysts acknowledge that the higher price target reflects a solid Q3, but emphasize that the implied upside is increasingly reliant on sustained execution against a still-early sales recovery.Narrative-Update • Nov 27
EKSO: Sales Recovery and Increased Confidence Will Drive Future Stock Performance
Analysts have raised their price target for Ekso Bionics from $6.75 to $7.75. This change reflects stronger revenue growth expectations and a solid recent earnings report.Analyseartikel • Aug 24
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 26% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...Narrative-Update • Aug 10
Advanced Exoskeleton Devices Will Broaden Rehabilitation Market Access
The drastic reduction in Ekso Bionics Holdings' consensus price target from $34.75 to $6.75 reflects sharply lower growth and earnings expectations as seen in the substantial drop in its forward P/E multiple from 24.94x to 4.86x. What's in the News Launched eksoUniversity, an online platform offering CEU-approved courses for physical therapists and assistants in over 30 states.Analyseartikel • Jun 22
Not Many Are Piling Into Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Stock Yet As It Plummets 31%
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 31% in the...Analyseartikel • Jun 22
Slammed 31% Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares are down a considerable 31...
Neues Narrative • May 01
PRIA Healthcare And National Seating Will Streamline Medicare Claims
Strategic partnerships aim to broaden distribution, streamline reimbursements, and enhance revenue growth in the personal health market.Analyseartikel • Mar 07
It's Down 27% But Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Could Be Riskier Than It Looks
Unfortunately for some shareholders, the Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) share price has dived 27% in the...Analyseartikel • Mar 06
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
It's been a sad week for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), who've watched their investment drop 17% to...Analyseartikel • Jan 12
Even With A 39% Surge, Cautious Investors Are Not Rewarding Ekso Bionics Holdings, Inc.'s (NASDAQ:EKSO) Performance Completely
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders are no doubt pleased to see that the share price has bounced...Analyseartikel • Nov 12
Take Care Before Jumping Onto Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Even Though It's 27% Cheaper
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shareholders that were waiting for something to happen have been dealt a...Analyseartikel • Aug 29
Investors Give Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Shares A 26% Hiding
Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) shares have had a horrible month, losing 26% after a relatively good period...Analyseartikel • Jul 13
Many Still Looking Away From Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.2x might make it look like a buy...Analyseartikel • May 02
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00
It's shaping up to be a tough period for Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ), which a week ago released some...Analyseartikel • Dec 20
Market Still Lacking Some Conviction On Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
You may think that with a price-to-sales (or "P/S") ratio of 1.3x Ekso Bionics Holdings, Inc. ( NASDAQ:EKSO ) is a...Analyseartikel • Jun 19
Sentiment Still Eluding Ekso Bionics Holdings, Inc. (NASDAQ:EKSO)
Ekso Bionics Holdings, Inc.'s ( NASDAQ:EKSO ) price-to-sales (or "P/S") ratio of 1.1x might make it look like a strong...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 31 | 1 | N/A | N/A | 1 |
| 12/31/2027 | 24 | -2 | N/A | N/A | 1 |
| 12/31/2026 | 23 | -4 | N/A | N/A | 2 |
| 3/31/2026 | 12 | -16 | -12 | -12 | N/A |
| 12/31/2025 | 13 | -12 | -12 | -12 | N/A |
| 9/30/2025 | 15 | -11 | -9 | -9 | N/A |
| 6/30/2025 | 15 | -11 | -9 | -9 | N/A |
| 3/31/2025 | 18 | -11 | -8 | -8 | N/A |
| 12/31/2024 | 18 | -11 | -10 | -10 | N/A |
| 9/30/2024 | 18 | -11 | -10 | -10 | N/A |
| 6/30/2024 | 18 | -12 | -11 | -11 | N/A |
| 3/31/2024 | 18 | -14 | -11 | -11 | N/A |
| 12/31/2023 | 18 | -15 | -12 | -12 | N/A |
| 9/30/2023 | 17 | -15 | -14 | -14 | N/A |
| 6/30/2023 | 16 | -16 | -14 | -13 | N/A |
| 3/31/2023 | 14 | -15 | -15 | -15 | N/A |
| 12/31/2022 | 13 | -15 | -15 | -15 | N/A |
| 9/30/2022 | 13 | -15 | -14 | -14 | N/A |
| 6/30/2022 | 13 | -12 | -14 | -14 | N/A |
| 3/31/2022 | 12 | -11 | -13 | -13 | N/A |
| 12/31/2021 | 11 | -10 | -11 | -11 | N/A |
| 9/30/2021 | 9 | -11 | -10 | -10 | N/A |
| 6/30/2021 | 9 | -6 | -9 | -9 | N/A |
| 3/31/2021 | 9 | -17 | -9 | -9 | N/A |
| 12/31/2020 | 9 | -16 | -9 | -9 | N/A |
| 9/30/2020 | 10 | -15 | -9 | -9 | N/A |
| 6/30/2020 | 11 | -17 | -12 | -12 | N/A |
| 3/31/2020 | 12 | -8 | -12 | -12 | N/A |
| 12/31/2019 | 14 | -12 | N/A | -16 | N/A |
| 9/30/2019 | 13 | -14 | N/A | -19 | N/A |
| 6/30/2019 | 13 | -21 | N/A | -19 | N/A |
| 3/31/2019 | 12 | -26 | N/A | -21 | N/A |
| 12/31/2018 | 11 | -27 | N/A | -22 | N/A |
| 9/30/2018 | 10 | -32 | N/A | -23 | N/A |
| 6/30/2018 | 10 | -31 | N/A | -27 | N/A |
| 3/31/2018 | 8 | -29 | N/A | -31 | N/A |
| 12/31/2017 | 7 | -29 | N/A | -31 | N/A |
| 9/30/2017 | 7 | -26 | N/A | -30 | N/A |
| 6/30/2017 | 7 | -31 | N/A | -28 | N/A |
| 3/31/2017 | 7 | -35 | N/A | -25 | N/A |
| 12/31/2016 | 14 | -34 | N/A | -25 | N/A |
| 9/30/2016 | 14 | -38 | N/A | -26 | N/A |
| 6/30/2016 | 15 | -31 | N/A | -24 | N/A |
| 3/31/2016 | 15 | -27 | N/A | -21 | N/A |
| 12/31/2015 | 9 | -24 | N/A | -18 | N/A |
| 9/30/2015 | 8 | -35 | N/A | -16 | N/A |
| 6/30/2015 | 7 | -18 | N/A | -15 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: EKSO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (3.4%).
Ertrag vs. Markt: EKSO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.
Hohe Wachstumserträge: EKSO wird voraussichtlich in den nächsten 3 Jahren rentabel werden.
Einnahmen vs. Markt: EKSODie Einnahmen des Unternehmens (23.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.6% pro Jahr).
Hohe Wachstumseinnahmen: EKSODie Einnahmen des Unternehmens (23.2% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von EKSO in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/04 14:21 |
| Aktienkurs zum Tagesende | 2026/05/04 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Ekso Bionics Holdings, Inc. wird von 7 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Gregory Chodaczek | B. Riley Securities, Inc. |
| Tom Grady | Edison Investment Research |
| Dan Scovel | Edison Investment Research |